Breast CarePub Date : 2026-10-19DOI: 10.1159/brc/abrag003
Lisa Vesenmayer, Simon Udovica, Kerstin Wimmer, Constantin Mannsbart, Katharina Kantner, Ruth Exner, Zsuzsanna Bago-Horvath, Stefan Konrad, Kathrin Strasser-Weippl, Christian F Singer, Leonhard Müllauer, Rupert Bartsch, Maximilian Marhold
{"title":"Retrospective Analysis of Real-World Elacestrant Use in Two Large Austrian Cancer Centers.","authors":"Lisa Vesenmayer, Simon Udovica, Kerstin Wimmer, Constantin Mannsbart, Katharina Kantner, Ruth Exner, Zsuzsanna Bago-Horvath, Stefan Konrad, Kathrin Strasser-Weippl, Christian F Singer, Leonhard Müllauer, Rupert Bartsch, Maximilian Marhold","doi":"10.1159/brc/abrag003","DOIUrl":"https://doi.org/10.1159/brc/abrag003","url":null,"abstract":"<p><strong>Introduction: </strong>Elacestrant is an oral selective estrogen receptor degrader (SERD) approved for the treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) following progression on endocrine therapy and CDK4/6 inhibitors. While randomized trial data from the EMERALD study demonstrated its clinical benefit, real-world evidence remains limited.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of patients with HR-positive/HER2-negative MBC treated with elacestrant at two large cancer centers in Vienna, Austria. Clinical outcomes and safety were evaluated in routine clinical practice by experienced oncologists.</p><p><strong>Results: </strong>Elacestrant demonstrated clinically meaningful efficacy in a heavily pretreated patient population of 30 patients with estrogen receptor 1 (ESR1) mutations. Median age was 65 years and the cohort was predominantly postmenopausal (86.7%). Before initiation of elacestrant, patients had received a median of two lines of endocrine therapy and one line of chemotherapy. Co-mutations of <i>ESR1</i>/<i>PIK3CA</i> were present in 33.3% of patients. Median progression-free survival (PFS) was 3.6 months (95% CI 2.96-4.24) and median overall survival was 20.2 months (95% CI 5.04-35.36). In univariate analyses, de novo metastatic disease and the presence of a single ESR1-mutated exon were associated with longer PFS, whereas the ESR1 E380Q mutation was associated with shorter PFS. Adverse events of any grade occured in 46.7% of patients. Within our cohort, a low rate of dose reductions (3.3%) was found. Subsequent therapies after elacestrant mainly consisted of antibody-drug conjugates (36.7% of patients) and chemotherapy (26.7%).</p><p><strong>Conclusion: </strong>In this real-world cohort, elacestrant showed effectiveness and tolerability similar to data observed in the EMERALD trial. Larger prospective real-world analyses are warranted to further validate these findings and define optimal patient selection.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Imaging Assessment of Residual Disease in Clipped Target Lymph Nodes after Neoadjuvant Chemotherapy for Breast Cancer: A Node-Level Validation Study.","authors":"Michiko Yamazaki, Rikiya Nakamura, Shouko Hayama, Hideyuki Yamada","doi":"10.1159/brc/abrag008","DOIUrl":"10.1159/brc/abrag008","url":null,"abstract":"<p><strong>Introduction: </strong>Accurate assessment of residual axillary disease after neoadjuvant chemotherapy (NAC) is critical for selecting candidates for tailored axillary surgery. However, the diagnostic performance of post-NAC imaging for residual disease in clipped metastatic lymph nodes remains unclear.</p><p><strong>Methods: </strong>We retrospectively analyzed 112 patients with biopsy-proven axillary lymph node metastasis who underwent clip placement in a target lymph node before NAC. After NAC, the clipped node was assessed using ultrasonography and computed tomography, and imaging findings were directly compared with the pathological status of the resected clipped node. Diagnostic performance was evaluated overall and according to breast cancer subtype. In addition, logistic regression-based prediction models were developed and internally validated using 5-fold cross-validation.</p><p><strong>Results: </strong>Among the 112 patients, 82 were classified as clinically node-negative and 30 as clinically node-positive after NAC. Post-NAC imaging showed a sensitivity of 38.8%, specificity of 82.5%, positive predictive value of 63.3%, negative predictive value of 63.4%, and accuracy of 63.4% for residual disease in the clipped node. Notably, imaging did not detect residual disease in 30 of 49 pathologically positive clipped nodes. Diagnostic performance varied according to subtype, with higher negative predictive value in HER2-positive tumors and lower negative predictive value in HR-positive/HER2-negative disease. Prediction models showed moderate discrimination, with 5-fold cross-validated AUCs of 0.79-0.81. The 6-variable model achieved the highest NPV of 0.88, although additional variables yielded only modest improvements over the baseline model.</p><p><strong>Conclusion: </strong>Post-NAC imaging of the clipped target lymph node frequently differed from the pathological findings of the same resected clipped metastatic lymph node. Residual disease may persist despite disappearance of nodal morphology, while pathological complete response may occur despite suspicious imaging findings. These limitations underscore the importance of pathological evaluation of the clipped node for safe axillary de-escalation. These findings have direct implications for surgical decision-making in axillary management after NAC.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-10-12DOI: 10.1159/brc/abrag002
Ying Yin, Jianming Yan, Jie Wang, Mingjie Yuan
{"title":"Development and Validation of a Lipid Metabolism-Related Gene Prognostic Model for Breast Cancer: Integrating Risk Score and Nomogram.","authors":"Ying Yin, Jianming Yan, Jie Wang, Mingjie Yuan","doi":"10.1159/brc/abrag002","DOIUrl":"10.1159/brc/abrag002","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is a leading cause of cancer death globally. Altered lipid metabolism drives tumor progression and therapy resistance. This study aimed to evaluate the prognostic value of lipid metabolism-related genes and build a predictive model for breast cancer.</p><p><strong>Methods: </strong>We integrated transcriptomic data from The Cancer Genome Atlas (TCGA) breast cancer cohort (<i>n</i> = 1,106) and normal breast tissue samples from both TCGA (<i>n</i> = 113) and the Genotype-Tissue Expression database (<i>n</i> = 162). After rigorous batch effect correction, we identified lipid metabolism-related differentially expressed genes (DEGs) by intersecting DEGs with a curated gene set from the Molecular Signatures Database. Univariate Cox regression analysis was employed to identify prognosis-associated genes, based on which a risk-scoring model was constructed. The cohort was randomly divided into training (70%, <i>n</i> = 738) and validation (30%, <i>n</i> = 311) sets. A nomogram was developed by integrating the risk score with key clinicopathological variables. Model performance was assessed using the concordance index, receiver operating characteristic curves, and calibration plots. Functional enrichment analyses were conducted to explore the biological significance of the identified genes.</p><p><strong>Results: </strong>From 169 lipid metabolism-related DEGs, 14 were linked to overall survival (OS). The risk model stratified patients into high- and low-risk groups with distinct survival (5-year OS: 72.1% vs. 91.2% in training; 77.2% vs. 89.9% in validation). The risk score was an independent prognostic factor (HR = 1.72). The nomogram showed good accuracy for 3-/5-year survival prediction (training area under the curves: 0.815, 0.797; validation: 0.805, 0.713). Protein-protein interaction analysis revealed a core protein module (SCARB2, AUH, ACADM, ACSF2) that was enriched in functional enrichment primarily in fatty acid β-oxidation and branched-chain amino acid degradation pathways.</p><p><strong>Conclusion: </strong>We developed a validated lipid metabolism-related gene signature and nomogram that reliably predicts OS in breast cancer, offering prognostic insights, though further external validation is warranted.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-09-12DOI: 10.1159/brc/abrag007
Maria Kersten, Thomas W P Friedl, Wolfgang Janni, Inga Bekes, Julia Haager, Visnja Fink
{"title":"Synthetic Mesh Use in Implant-Based Breast Reconstruction after Mastectomy: What Determines the Surgical Outcome?","authors":"Maria Kersten, Thomas W P Friedl, Wolfgang Janni, Inga Bekes, Julia Haager, Visnja Fink","doi":"10.1159/brc/abrag007","DOIUrl":"10.1159/brc/abrag007","url":null,"abstract":"<p><strong>Introduction: </strong>Synthetic mesh is frequently used in immediate implant-based breast reconstruction following skin-sparing or nipple-sparing mastectomy to enable immediate reconstruction, though concerns persist regarding associated complications.</p><p><strong>Methods: </strong>We conducted a retrospective single-center registry study involving 220 consecutive patients, of whom 123 (55.9%) received synthetic mesh: 92 with semi-resorbable (Seragyn®) and 31 with non-resorbable (TiLOOP®) mesh.</p><p><strong>Results: </strong>Postoperative complications occurred in 90 patients (40.9%), with seroma formation as the primary contributor to morbidity (58.8%). No significant difference in overall complication rates was found between patients with or without mesh (44.7% vs. 36.1%, <i>p</i> = 0.196) or between mesh types (44.6% vs. 45.2%, <i>p</i> = 0.954). Rates of revision surgery, infection, wound healing disorders, capsular contracture, and seroma did not differ significantly between groups (all <i>p</i> > 0.05). Multivariable analysis identified obesity (BMI ≥30 kg/m<sup>2</sup>) as a significant predictor of both overall complications and seroma. Radiation therapy increased the risk of revision surgery. Age, smoking status, surgical laterality, implant location, and primary systemic therapy had no significant impact.</p><p><strong>Conclusion: </strong>The use of synthetic mesh, whether semi-resorbable or non-resorbable, does not significantly affect the risk of postoperative complications in breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (NSM). Therefore, surgical planning should prioritize oncologic safety, esthetic outcomes, and individual patient factors. Shared decision-making remains essential in choosing the optimal reconstructive approach.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13686646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-08-25DOI: 10.1159/brc/abrag005
Maria Eleni Hatzipanagiotou, Lisa Witterauf, Mikosch Augele, Aviva Fischer, Ivana Holzhauser, Ines Schönbuchner, Simone Hammer, Miriam Fernandez-Pacheco, Deborah Huber, Bernhard H F Weber, Davor Lessel, Olaf Ortmann, Stephan Seitz
{"title":"Tumor Biology, Genetic Risk, and Systemic Therapy in Familial Breast Cancer: An 8-Year Experience from a German Center for Familial Breast and Ovarian Cancer.","authors":"Maria Eleni Hatzipanagiotou, Lisa Witterauf, Mikosch Augele, Aviva Fischer, Ivana Holzhauser, Ines Schönbuchner, Simone Hammer, Miriam Fernandez-Pacheco, Deborah Huber, Bernhard H F Weber, Davor Lessel, Olaf Ortmann, Stephan Seitz","doi":"10.1159/brc/abrag005","DOIUrl":"https://doi.org/10.1159/brc/abrag005","url":null,"abstract":"<p><strong>Introduction: </strong>Approximately 30% of breast cancer cases involve a significantly increased familial risk, often associated with pathogenic germline mutations. This study evaluates the spectrum of pathogenic variants identified, systemic therapy patterns, tumor biology, and treatment response among breast cancer patients treated at the Regensburg Center of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) between 2012 and 2020.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 385 breast cancer patients who met the GC-HBOC criteria for elevated familial risk. Patients were categorized based on genetic status (pathogenic <i>BRCA1/2-</i>variants, pathogenic variants in other breast and ovarian cancer-related genes such as <i>CHEK2</i>, <i>ATM</i>, <i>PALB2</i>, <i>RAD51C</i>, <i>RAD51D</i>, or <i>BARD1</i> [<i>BRCA</i>-related], or negative) and tumor subtype (triple-negative breast cancer [TNBC], hormone receptor-positive/HER2-negative [HR+/HER2-], or HER2-positive [HER2+]). The use of chemotherapy, including platinum-based regimens, and rates of pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) were analyzed.</p><p><strong>Results: </strong>In this study, pathogenic variants in established breast and ovarian cancer-predisposing genes were identified in 49%, primarily in <i>BRCA1</i> and <i>BRCA2</i> (36%). TNBC was predominant in <i>BRCA1</i>-positive patients (61%), whereas <i>BRCA2</i>-positive and variant-negative patients more commonly presented with HR+/HER2- tumors. Chemotherapy was administered in 76% of patients, with the highest rate in <i>BRCA1</i> carriers (89%). The use of platinum-based chemotherapy increased significantly among TNBC patients after 2014, reaching 100% by 2020. Among 144 patients who received NACT, 22% achieved a pCR. <i>BRCA1</i>-positive patients had the highest pCR rate (35%), with TNBC/<i>BRCA1</i>-positive patients achieving a pCR in 67% of cases.</p><p><strong>Conclusion: </strong>The study demonstrates the effective implementation of genetic testing and guideline-based therapy in a real-world, high-risk breast cancer cohort. <i>BRCA1</i>-associated TNBC exhibited the highest chemotherapy sensitivity, as evidenced by elevated pCR rates. However, incomplete documentation of treatment outcomes somewhat limits the strength of the latter. Overall, these findings reinforce the value of personalized treatment strategies in hereditary breast cancer and underscore the need for more comprehensive real-world data collection to optimize patient management.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-08-25DOI: 10.1159/brc/abrag004
Anna-Christina Rambow, Tim Jannik Schröder, Gudrun Wagenpfeil, Peer Jansen, Huy Duc Le, Christoph Rogmans, Nils Tribian, Nicolai Maass, Marion van Mackelenbergh
{"title":"CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data.","authors":"Anna-Christina Rambow, Tim Jannik Schröder, Gudrun Wagenpfeil, Peer Jansen, Huy Duc Le, Christoph Rogmans, Nils Tribian, Nicolai Maass, Marion van Mackelenbergh","doi":"10.1159/brc/abrag004","DOIUrl":"https://doi.org/10.1159/brc/abrag004","url":null,"abstract":"<p><strong>Introduction: </strong>CDK4/6 inhibitors (CDK4/6i) are standard first-line treatment for hormone receptor-positive, HER2-negative metastatic breast cancer. Real-world data (RWD) remain crucial to evaluate performance in clinical routine practice. This study updates a previous analysis to evaluate progression-free survival (PFS), prognostic factors, and safety.</p><p><strong>Methods: </strong>This retrospective analysis included 265 MBC patients from the University Medical Center Schleswig-Holstein, Kiel, treated with a CDK4/6i between 11/2016 and 09/2024.</p><p><strong>Results: </strong>Of 265 patients, 30.6% had de novo and 69.4% secondary metastatic disease. Due to adverse events (AEs), 17.7% discontinued therapy and 5.0% switched drugs. Median follow-up was 45 months. In the overall cohort, median PFS was 24 months, and median overall survival was 73 months. PFS did not differ significantly between abemaciclib, palbociclib, and ribociclib. Improved PFS was associated with earlier treatment initiation (first-line 27 vs. ≥ third-line 10 months; <i>p</i> < 0.001). The occurrence of lung (15 vs. 27 months; <i>p</i> < 0.001) and liver metastases (10 vs. 29 months; <i>p</i> < 0.001) before initiation of CDK4/6i therapy was associated with a shorter median PFS. Conversely, dose reductions due to AEs significantly prolonged PFS (33 vs. 14 months; <i>p</i> < 0.001). Hematological toxicity was the most frequent AE.</p><p><strong>Conclusion: </strong>This RWD analysis confirms the safety and efficacy of CDK4/6i in routine clinical practice, showing narrower PFS gaps to pivotal trials than previously reported. Visceral metastases predicted poorer outcomes, while dose reductions independently correlated with longer PFS, supporting individualized therapy management.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-08-03DOI: 10.1159/brc/abrag001
Heleen Leurs, Chris Monten, Melanie Machiels, Marianne Hanssens, Sarah Moonen, Marie Ham, Erik Fransen, Nick Gebruers, Tessa De Vrieze
{"title":"A Multicentre Randomised Controlled Trial Protocol Investigating the Effectiveness of Kinesio Taping in Persistent Breast and Truncal Oedema.","authors":"Heleen Leurs, Chris Monten, Melanie Machiels, Marianne Hanssens, Sarah Moonen, Marie Ham, Erik Fransen, Nick Gebruers, Tessa De Vrieze","doi":"10.1159/brc/abrag001","DOIUrl":"10.1159/brc/abrag001","url":null,"abstract":"<p><strong>Introduction: </strong>Persistent breast and truncal oedema is a burdensome complication following breast cancer treatment. Current therapies are often expensive, time-intensive or lack evidence, underscoring the need for innovative and cost-effective solutions. Kinesio taping has gained attention as a potential supportive intervention, yet high-quality evidence regarding its effectiveness is lacking.</p><p><strong>Methods: </strong>This multicentre, randomised controlled trial will enrol 128 women with chronic breast and/or truncal oedema following breast cancer treatment. Participants will be randomised (1:1) to receive either decongestive lymphatic therapy alone (control group) or in combination with kinesio taping (intervention group). The intervention phase will last 4 weeks, during which participants will attend two physiotherapy sessions per week. In the intervention group, kinesio tape will be applied twice a week for 3 consecutive days. After completion of this phase, participants will enter a 6-month observational follow-up period. The primary outcome is symptom severity, assessed using the Breast Edema Questionnaire. Secondary outcomes include pain, local tissue water and quality of life, measured by the Visual Analogue Scale, Tissue Dielectric Constant, EORTC QLQ-BR23, and EQ-5D-5L. Assessments will be conducted at baseline, post-intervention, and at 3 and 6 months of follow-up.</p><p><strong>Conclusion: </strong>This will be the first randomised controlled trial to evaluate the effectiveness of kinesio taping as an adjunct to standard care for chronic breast and truncal oedema. If proven effective, kinesio taping could offer a low-cost, accessible and well-tolerated additional treatment option to improve symptom management and quality of life in breast cancer survivors.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-07-24DOI: 10.1159/000553131
Ariana Plasger, Sarah Meurer, Marie-Kristin von Wahlde, Ludwig Kiesel, Isabel Radke, Carl Opitz, Wolfgang Roll, Lars Hanker, Joke Tio
{"title":"Clinical Relevance of HER2-Low and HER2-Zero Subgroups in Hormone Receptor-Negative Breast Cancer: A Retrospective Single-Center Cohort Study 2014-2024.","authors":"Ariana Plasger, Sarah Meurer, Marie-Kristin von Wahlde, Ludwig Kiesel, Isabel Radke, Carl Opitz, Wolfgang Roll, Lars Hanker, Joke Tio","doi":"10.1159/000553131","DOIUrl":"10.1159/000553131","url":null,"abstract":"<p><strong>Introduction: </strong>HER2-negative and hormone receptor (HR)-negative breast cancer is typically associated with poor prognosis due to limited treatment options. Recent research has demonstrated efficacy of anti-HER2 antibody-drug conjugates in patients with HER2-low (HER2 1+ and HER2 2+/ISH-negative) breast cancer, suggesting this subgroup as a distinct clinical and biological entity with actionable therapeutic targets. Retrospective analyses of cohorts prior to the introduction of targeted agents in HER2-low patients are essential to establish natural disease course and prognostic relevance of this subgroup independent of targeted therapy.</p><p><strong>Methods: </strong>We retrospectively analyzed data of HR-negative and either HER2-zero or HER2-low breast cancer patients treated in a single clinical center between 2014 and 2024. Primary endpoints included overall survival (OS) and event-free survival (EFS), secondary endpoints included pathological complete response (pCR) after neoadjuvant chemotherapy and clinicopathological characteristics across the HER2 subgroups.</p><p><strong>Results: </strong>Among 277 patients, 160 (57.8%) had HER2-zero, 75 (27.1%) had HER2 1+ and 42 (15.2%) HER2 2+/ISH-negative tumors. Higher tumor stages (<i>p</i> = 0.053) and lower Ki-67 indices (<i>p</i> = 0.038) were notably more prevalent in HER2 2+/ISH-negative patients. OS was significantly worse in HER2 2+/ISH-negative patients (HR 8.12, 95% CI: 1.98-33.37, <i>p</i> = 0.004), whereas EFS and pCR rates did not differ significantly across the HER2 subgroups. Patients with pCR after neoadjuvant chemotherapy had significantly better OS (<i>p</i> = 0.007) and EFS (<i>p</i> = 0.003) compared to those with non-pCR, without differences observed among the HER2 subgroups.</p><p><strong>Conclusions: </strong>HER2 2+/ISH-negative status was associated with poorer OS. While EFS and pCR rates also tended to be lower, the differences were not statistically significant. Distinct clinicopathological features associated with lower pCR rates may have contributed to the inferior survival in this group.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-07-18DOI: 10.1159/000552139
Laura García-Garcés, Raquel Carcelén-González, María Inmaculada Sánchez-López, Cayetana Ruíz-Zaldíbar, María Rovira Navalón, Laura Pérez Lledó, Ana Belén Gil Moreno, Marina Jaime Arranz, María Dolores Rodríguez Sánchez, María José Díaz Gutiérrez, Marta Lluesma-Vidal
{"title":"The Impact of Nipple-Areolar Complex Micropigmentation on the Health of Mastectomised Breast Cancer Survivors: Protocol for a Multicentre Descriptive Prospective Cohort Study.","authors":"Laura García-Garcés, Raquel Carcelén-González, María Inmaculada Sánchez-López, Cayetana Ruíz-Zaldíbar, María Rovira Navalón, Laura Pérez Lledó, Ana Belén Gil Moreno, Marina Jaime Arranz, María Dolores Rodríguez Sánchez, María José Díaz Gutiérrez, Marta Lluesma-Vidal","doi":"10.1159/000552139","DOIUrl":"10.1159/000552139","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer survivors often face physical changes that affect their psychological and social well-being. Among these, the loss of the nipple-areolar complex (NAC) can significantly impact body image, self-esteem, and intimate relationships. To address this, surgical reconstruction techniques have evolved, with micropigmentation or tattooing of the NAC emerging as a preferred method due to its simplicity, natural appearance, and minimal invasiveness.</p><p><strong>Methods: </strong>This study is a multicentre, descriptive, prospective cohort study conducted in Spain. It aims to evaluate the impact of NAC micropigmentation on body image, self-esteem, sexual function, and partner interaction among mastectomised breast cancer survivors. Participants will be women over 18 who have undergone mastectomy and are receiving NAC micropigmentation for the first time. They must have a good understanding of Spanish and internet access. Exclusion criteria include prior NAC tattooing, pregnancy, breastfeeding, or refusal to participate. An initial pilot phase involving 30 participants was used to estimate the necessary sample size. Power calculations based on these preliminary data established a recruitment target of 164 participants Recruitment is consecutive, and ethical approval has been obtained from all participating hospitals.</p><p><strong>Conclusion: </strong>The study addresses a critical gap in post-mastectomy care by focusing on the final phase of breast reconstruction. It highlights the growing popularity of NAC micropigmentation and its potential to enhance psychological recovery and quality of life. Findings may inform future clinical practices and improve patient satisfaction in breast cancer care.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2026-07-17DOI: 10.1159/000552733
Caglar Kazim Pekuz, Mahmut Zenciroglu, Serdar Basim, Pelin Basim
{"title":"Differences in Biomarkers between the Primary Tumor and Axillary Lymph Nodes in Invasive Lobular Carcinoma: A Retrospective Study.","authors":"Caglar Kazim Pekuz, Mahmut Zenciroglu, Serdar Basim, Pelin Basim","doi":"10.1159/000552733","DOIUrl":"10.1159/000552733","url":null,"abstract":"<p><strong>Introduction: </strong>Invasive lobular carcinoma (ILC) is a distinct histological subtype of breast cancer characterized by hormone receptor positivity, low proliferative activity, and unique metastatic patterns. However, recent evidence suggests that biomarker profiles in metastatic sites may differ from those in primary tumors, potentially reflecting biological heterogeneity.</p><p><strong>Methods: </strong>A retrospective review was conducted on 108 patients diagnosed with ILC who underwent immunohistochemical evaluation of both primary breast tumor and metastatic axillary lymph node specimens between 2012 and 2021. Differences in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression were analyzed using paired statistical tests, including McNemar's and Wilcoxon signed-rank tests. Subgroup analyses were performed according to the receipt of neoadjuvant chemotherapy (NeoCT), although findings in the NeoCT subgroup were interpreted as exploratory because treatment may influence biomarker expression. Histological grade was also evaluated, and its association with primary tumor Ki-67 was analyzed exploratorily.</p><p><strong>Results: </strong>No significant differences were observed in ER, PR, or HER2 expression between primary tumors and metastatic axillary lymph nodes (<i>p</i> > 0.05). However, a significant increase in the Ki-67 proliferation index was found in metastatic lymph nodes compared with matched primary tumors (median 28% vs. 18%, <i>p</i> < 0.001). Consequently, 37.9% of patients exhibited a surrogate molecular subtype conversion from Luminal A-like to Luminal B-like. Histological grade was significantly associated with primary tumor Ki-67, with median values of 10%, 12.5%, and 32.5% for grade 1, grade 2, and grade 3 tumors, respectively (<i>p</i> = 0.00014).</p><p><strong>Conclusion: </strong>Metastatic axillary lymph nodes in ILC display higher proliferative activity compared to primary tumors, resulting in a substantial rate of conversion from Luminal A-like to Luminal B-like. These findings support biological heterogeneity between primary and nodal disease; however, their direct prognostic and therapeutic implications remain uncertain.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}